Protalix BioTherapeutics, Inc. (PLX)

ASE – Real vaqt narxi. Valyuta: USD

2.62

+0.18 (7.61%)

Yopilishda: Aug 12, 2026, 3:59 PM EDT

2.62

-0.00 (-0.05%)

Bozordan keyin: Aug 12, 2026, 5:11 PM EDT

12.08.2026

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio® Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone payment Year-to-date, the Company achieved profitability with a net income of $22.1 million The Company reiterates full-year 2026 guidance of $78.0 million to $83.0 million in total revenue PRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027 Cash, cash equivalents, and short-term bank deposits were $40.7 million as of June 30, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115 CARMIEL, Israel, Aug. 12, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the second quarter ended June 30, 2026, and provided a business and clinical update.

05.08.2026

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, Aug. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended June 30, 2026 and provide a business update on August 12, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

12.08.2026

Protalix BioTherapeutics, Inc. (PLX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

Videolar

No Data

Press-relizlar

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

Videolar

No Data

Press-relizlar

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Search stocks

Protalix BioTherapeutics, Inc. (PLX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

Videolar

No Data

Press-relizlar

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

Videolar

No Data

Press-relizlar

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results